News
MDCX
0.4460
-8.57%
-0.0418
Weekly Report: what happened at MDCX last week (0622-0626)?
Weekly Report · 1d ago
Medicus Pharma to present at Bio International Conference, outlining SkinJect registrational plan
PUBT · 06/22 11:30
Weekly Report: what happened at MDCX last week (0615-0619)?
Weekly Report · 06/22 10:01
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Barchart · 06/22 06:30
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
Barchart · 06/20 12:30
Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA
TipRanks · 06/15 11:51
Medicus Pharma submits FDA rare pediatric disease designation request for SkinJect in Gorlin syndrome
PUBT · 06/15 11:30
MEDICUS PHARMA ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) SUBMISSION OF RARE PEDIATRIC DISEASE DESIGNATION REQUEST FOR SKINJECT® IN GORLIN SYNDROME
Reuters · 06/15 11:30
Weekly Report: what happened at MDCX last week (0608-0612)?
Weekly Report · 06/15 10:02
Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial
PUBT · 06/11 11:30
MEDICUS PHARMA INITIATES GROUNDBREAKING PRECISION-E2 PHASE 2A STUDY OF TEVERELIX® IN ENDOMETRIOSIS UTILIZING THE EMIRATI GENOME PROGRAM
Reuters · 06/11 11:30
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Barchart · 06/11 06:30
Medicus Pharma submits substantial modification application through EU CTIS
TipRanks · 06/08 11:37
Medicus Pharma submits EU CTIS application to amend Teverelix Phase 2b trial plan
PUBT · 06/08 11:30
MEDICUS PHARMA ADVANCES TEVERELIX® PROGRAM TOWARDS REGISTRATIONAL DEVELOPMENT TARGETING HIGH CARDIOVASCULAR-RISK PROSTATE CANCER PATIENTS WITH KEY EUROPEAN SUBMISSION
Reuters · 06/08 11:30
Weekly Report: what happened at MDCX last week (0601-0605)?
Weekly Report · 06/08 09:59
New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
Barchart · 06/06 06:20
Medicus Pharma Shareholders Approve Auditor, Board and Consolidation
TipRanks · 06/04 22:34
Medicus Pharma shareholders approve board authority for up to 1-for-50 share consolidation
PUBT · 06/04 20:32
Analysts Are Bullish on Top Healthcare Stocks: Health Catalyst (HCAT), Medicus Pharma Ltd (MDCX)
TipRanks · 06/04 15:20
More
Webull provides a variety of real-time MDCX stock news. You can receive the latest news about Medicus Pharma Ltd through multiple platforms. This information may help you make smarter investment decisions.
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.